Biogen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Biogen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. 

CEO
Christopher A. Viehbacher
CEOChristopher A. Viehbacher
Employees
7,605
Employees7,605
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
1978
Founded1978
Employees
7,605
Employees7,605

BIIB Key Statistics

Market cap
21.66B
Market cap21.66B
Price-Earnings ratio
13.99
Price-Earnings ratio13.99
Dividend yield
Dividend yield
Average volume
1.32M
Average volume1.32M
High today
$149.12
High today$149.12
Low today
$146.25
Low today$146.25
Open price
$147.37
Open price$147.37
Volume
1.37M
Volume1.37M
52 Week high
$187.58
52 Week high$187.58
52 Week low
$110.04
52 Week low$110.04

BIIB News

Simply Wall St 18h
Biogen Valuation in Focus After New Dravet Syndrome Data Shows Extended Clinical Benefit

Biogen (BIIB) shares are in focus after new clinical data showed extended improvements for Dravet syndrome patients taking zorevunersen. The findings, presented...

Biogen Valuation in Focus After New Dravet Syndrome Data Shows Extended Clinical Benefit
TipRanks 19h
Biogen to present additional results from Phase 3 study of dapirolizumab pegol

Biogen (BIIB) announced upcoming presentations from studies evaluating dapirolizumab pegol, a novel Fc-free anti-CD40L drug candidate, in systemic lupus erythem...

TipRanks 3d
Biogen’s Hold Rating Justified by Limited Growth Prospects and Pipeline Uncertainty

Tim Anderson, an analyst from Bank of America Securities, reiterated the Hold rating on Biogen. The associated price target remains the same with $167.00. Eleva...

Analyst ratings

51%

of 37 ratings
Buy
48.6%
Hold
51.4%
Sell
0%

More BIIB News

The Motley Fool 3d
J.L. Bainbridge Exits Most of Biogen Stake as Biotech Stock Eyes Turnaround

Florida-based wealth advisory J. L. Bainbridge & Co. sold 119,376 shares of Biogen (BIIB 0.58%) during the third quarter for an estimated $16.1 million. What H...

J.L. Bainbridge Exits Most of Biogen Stake as Biotech Stock Eyes Turnaround
Simply Wall St 4d
Will LEQEMBI IQLIK’s At-Home Launch Redefine Biogen’s Alzheimer’s Treatment Story?

Eisai and Biogen announced in early October that the U.S. launch of LEQEMBI IQLIK, a subcutaneous autoinjector formulation for Alzheimer’s disease, has begun, w...

Will LEQEMBI IQLIK’s At-Home Launch Redefine Biogen’s Alzheimer’s Treatment Story?

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.